Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer

BACKGROUND: For small cell lung cancer (SCLC) therapy, immunotherapy might have unique advantages to some extent. Galectin-9 (Gal-9) plays an important role in antitumor immunity, while little is known of its function in SCLC. MATERIALS AND METHODS: By mean of immunohistochemistry (IHC), we tested t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peixin, Zhang, Liping, Zhang, Wei, Sun, Chenglong, Wu, Chunyan, He, Yayi, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577067/
https://www.ncbi.nlm.nih.gov/pubmed/33082168
http://dx.doi.org/10.1136/jitc-2020-001391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577067/
https://www.ncbi.nlm.nih.gov/pubmed/33082168
http://dx.doi.org/10.1136/jitc-2020-001391

Ejemplares similares